About
Igniting the power of passionate teams to help patients live longer and healthier lives.
Michael Betel is the President of Fatty Liver Alliance, a not-for-profit, registered charity, that raises awareness and educates the public about fatty liver disease. He is based in Toronto, where he increases the visibility of the disease and advocates for more research and resources to help patients in need.
Michael is a passionate advocate for those living with fatty liver disease and is dedicated to improving the lives of those affected by the condition. He has been instrumental in organizing events and initiatives to educate and inform the public about the disease and its impact on individuals and families.
In addition to his work with Fatty Liver Alliance, Michael is also a respected speaker and commentator on fatty liver disease and related topics. He has been featured in various media outlets, including newspapers, radio, and television, and has spoken at conferences and other events to raise awareness about the disease.
With 20+ years in Virology, GI, Oncology and Healthcare, Michael prepares organizations for the future with thoughtful short and long-term planning, designed to support the corporate mission with challenging goals. Lead organizations through periods of substantial growth and transition, with full accountability for budgeting, management, and reinforcing fiscal responsibility. Experienced in profit and nonprofit organizations, including pharmaceutical and healthcare.
Track record of building high-performing teams by selecting, developing, coaching, and mentoring sales leaders. Inspire excellence by igniting the power to overcome barriers and focus on customer centricity.
Advocate for criticality of empowering teams to develop, maintain, and use systems and resources to thrive, achieve excellence, and exceed organizational strategic plan objectives.
Known for tenacity and endless passion for delivering results. Dedicated consensus-builder who leads by example, promoting collaboration and valuing the fine balance between head and heart.
Skills & Expertise:
Business Development | Leadership & Strategic Planning | Pharmaceutical Sales and Marketing Management & Coaching | Contract Management & Negotiation | Customer Centricity | Product Launch | Liver Disease | Ad Boards | NASH | Virology | Hepatology | Oncology | Thought Leader Liaison | Creator of NASHnet.ca I Founder of Fatty Liver Alliance I Hepatitis C
Articles by Michael
-
The Challenges of Connecting with Physicians in a Covid-19 World
The Challenges of Connecting with Physicians in a Covid-19 World
By Michael Betel
Contributions
-
What are some design thinking strategies for creating adaptable outreach programs?
The only way to really understand your audience, and let’s for this discussion focus on the patient journey, is to spend time with them. Patient Advisory Boards will enlighten you about critical aspects of this audience that may never have been considered. One example would be about clinical study inclusion and the barriers, burdens and boundaries for patients and their families. Uncertainty and fear of the unknown, medical and health related factors like symptoms and comorbidities, logistical and practical challenges, like other medical conditions, informed consent and decision making, concerns about receiving a placebo are just a few examples to consider. Please include patients.
-
How can you build trust and credibility in a networked leadership role?
Consistency in messaging and truth in what you say and what you do is everything. Reputations are incredibly important and it is only over time that trust can be built. Being authentic and honest and really caring about others is the way to build long-term relationships that matter.
-
What are some effective ways to balance a nonprofit leadership position with your personal life?
I live by the belief that if you love what you do it isn't really work. Making a difference in the lives of patients and their families is rewarding 24/7 and is part of who I am. When your family is supportive and contributes to your vision as a not-for-profit leader, it is a win-win.
-
What are the latest trends in nonprofit branding and storytelling?
In the medical sector, and in our case, liver disease, patients who have shared their journey struggles have really made a difference in the lives of other patients, and as impactful with Physicians by giving them insights into their patients and how a ‘tailored approach’ to care can make all the difference.
Activity
-
S5-E24 - 𝗔 𝗩𝗶𝗲𝘄 𝗼𝗳 𝗠𝗔𝗦𝗟𝗗: Looking Back at EASL Congress From Six Weeks Later PharmaNest Founder and CEO Mathieu Petitjean and Global…
S5-E24 - 𝗔 𝗩𝗶𝗲𝘄 𝗼𝗳 𝗠𝗔𝗦𝗟𝗗: Looking Back at EASL Congress From Six Weeks Later PharmaNest Founder and CEO Mathieu Petitjean and Global…
Liked by Michael Betel
-
🌍 It’s Time for Action: World Hepatitis Day in 🇲🇰 🌍 supported by 🇪🇺🇺🇳 An Explosion of Action and Awareness! On July 28, we join the global…
🌍 It’s Time for Action: World Hepatitis Day in 🇲🇰 🌍 supported by 🇪🇺🇺🇳 An Explosion of Action and Awareness! On July 28, we join the global…
Liked by Michael Betel
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Licenses & Certifications
Volunteer Experience
-
Chair, Liver Action Network
Global Liver Institute
- Present 1 year 9 months
Health
In 2021, GLI launched the Liver Action Network (LAN) to meet the rapidly growing need for a coalition of community based organizations across the United States and abroad. Collectively, the LAN facilitates grassroot efforts to advance liver policy at the local, state, national and international levels. The LAN is an affiliation model that facilitates strategic mentorship, technical assistance, and financial support to community organization members, and affords a central structure for the…
In 2021, GLI launched the Liver Action Network (LAN) to meet the rapidly growing need for a coalition of community based organizations across the United States and abroad. Collectively, the LAN facilitates grassroot efforts to advance liver policy at the local, state, national and international levels. The LAN is an affiliation model that facilitates strategic mentorship, technical assistance, and financial support to community organization members, and affords a central structure for the formulation of policy positions and programmatic solutions by advocates. LAN is a first-of-its-kind network that provides community member organizations a central structure for the formulation of collective policy positions and programmatic solutions.
-
Reviewer
Nature Portfolio
- Present 2 months
Health
Peer reviewer: Communications Medicine. July 2024.
-
Community Advisory Board member
Canadian Association for the Study of the Liver
- Present 1 year 7 months
Health
-
Member
Global NASH Council
- Present 9 months
Health
The Global NASH Council ™ has been formed to bring together international experts to discuss, collaborate and contribute to the field of NASH. Given the global nature of NAFLD and NASH, it is important to include perspectives from different regions of the world, assess the clinical and economic impact of NASH which are based on the realities of each country and region.
* Member of the Patient Advisory Committee.
* Member of Hepatology Non-Hepatology Interface Committee. -
Patient Synergy Partnership
EASL | The Home of Hepatology
- Present 7 months
Health
We share goals to raise awareness, advocate for treatment access, and support research to beat Steatotic Liver Disease. Together, we envision a future where this condition is preventable, and every patient in need has access to the best tailored care possible.
-
-
-
-
-
-
-
Consultant Volunteer
American Association for the Study of Liver Diseases (AASLD)
- Present 1 year 8 months
Health
Collaborator on the Fatty Liver Disease Research and Action Priorities consensus statement.
-
Member
Obesity Canada – Obésité Canada
- Present 2 years 8 months
Health
Canadian Obesity Advocacy Network (COAN) member.
The Canadian Obesity Advocacy Network (COAN) is a diverse group of organizations that have come together with the purpose of changing the narrative of obesity in Canada. Participants include health professional associations committed to addressing obesity issues, education, and advocacy. -
-
Participant Delphi expert panel developing consensus around the nomenclature of NAFLD
American Association for the Study of Liver Diseases (AASLD)
- Present 2 years 5 months
Health
I participated in 4 Delphi sessions, one in-person 2 days workshop as part of the process of consensus statement development for the nomenclature of NAFLD.
Our aim is to produce a consensus statement on the current and potential future nomenclature of NAFLD based on input from a broad, multidisciplinary, global panel of experts. We anticipate some 40-45 statements across key categories (assessment of current nomenclature; stigma associated with aspects of the nomenclature; evaluation of…I participated in 4 Delphi sessions, one in-person 2 days workshop as part of the process of consensus statement development for the nomenclature of NAFLD.
Our aim is to produce a consensus statement on the current and potential future nomenclature of NAFLD based on input from a broad, multidisciplinary, global panel of experts. We anticipate some 40-45 statements across key categories (assessment of current nomenclature; stigma associated with aspects of the nomenclature; evaluation of the role of alcohol as a disease cofactor; assessment of impact of a name change on therapeutic development; assessment of the impact of a name change on disease awareness; assessment of MAFLD as an acceptable nomenclature to replace NAFLD; assessment of alternate names to replace NAFLD). -
Participant in NASH consensus statement development.
EASL | The Home of Hepatology
Health
The European Association for the Study of the Liver (EASL), under the umbrella of Healthy Livers, Healthy Lives: A Global Coalition for Action on Fatty Liver Disease, in the development of a global fatty liver disease research and action priorities agenda.
This global coalition will act as a platform for collective thinking and action. While EASL is coordinating this effort, the global coalition will be a collective effort led by the major liver associations.
-
Fundraiser
Canadian Liver Foundation
- 5 months
Health
Helping the Ottawa chapter raise much needed funds in 2020.
-
Board of Directors. National Marketing and Communications Committee Member. Strategy Committee Member.
Canadian Liver Foundation
- 8 years 11 months
Health
Received 50th Anniversary Recognition medal for long-standing service to community (2019).
Received Certificate of Appreciation in recognition for LIVERight Gala Guest Speaker (2019)
The CLF mandate is to promote liver health and reduce the incidence and impact of liver disease by providing support for research and education into the causes, diagnoses, prevention and treatment of liver disease.
As a Member of the Board of Directors, and a member of the National Marketing &…Received 50th Anniversary Recognition medal for long-standing service to community (2019).
Received Certificate of Appreciation in recognition for LIVERight Gala Guest Speaker (2019)
The CLF mandate is to promote liver health and reduce the incidence and impact of liver disease by providing support for research and education into the causes, diagnoses, prevention and treatment of liver disease.
As a Member of the Board of Directors, and a member of the National Marketing & Communications Committee and the Strategy Committee, I advised and assisted The Canadian Liver Foundation with the mandate to promote liver health and reduce the incidence and impact of liver disease by providing support for research and education into the causes, diagnoses, prevention and treatment of liver disease. -
Assistant Coach with North Toronto Baseball Association
North Toronto Baseball Camp
- 3 months
Children
Fabulous leadership opportunity to work with community children, building their confidence and skillsets in a sports setting.
Publications
-
Opportunities and challenges following approval of resmetirom for MASH liver disease
Nature
The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
Other authors -
-
A global action agenda for turning the tide on fatty liver disease
Hepatology
This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels
Other authors -
-
A global research priority agenda to advance public health responses to fatty liver disease
An estimated 38% of adults worldwide have non-alcoholic fatty liver disease (NAFLD). From individual impacts to widespread public health and economic consequences, the implications of this disease are profound. This study aimed to develop an aligned, prioritised fatty liver disease research agenda for the global health community.
Other authors -
-
Letter to the Editor: People living with HIV and NAFLD—A population left behind in the global effort for liver fibrosis screening?
Hepatology
“Based on current evidence, PWH should be considered an at-risk population and targeted for screening strategies for liver fibrosis. We believe that their inclusion in the guidelines will also help address current gaps in the pathogenesis and natural history of HIV-associated NASH. Moreover, PWH is currently excluded from the global effort of therapeutic trials for NASH.”
Other authors -
-
A global research priority agenda to advance public health responses to fatty liver disease
Journal of Hepatology
“Conclusions: Adopting this multidisciplinary consensus-built research priorities agenda can deliver a step-change in addressing fatty liver disease, mitigating against its individual and societal harms and proactively altering its natural history through pre-vention, identification, treatment, and care. This agenda should catalyse the global health community's efforts to advance and accelerate responses to this widespread and fast-growing public health threat.”
Other authors -
-
Facebook is an Informative Source for NASH Patient Market Research
Canadian Liver Journal
Facebook users who belong to a NASH support group seem to be more likely aware of what fatty liver disease is, and indicated that diet and exercise are helpful. Most have never spoken to a physician about fatty liver disease even though they are at high risk. Encouraging patients to join online NASH/NAFLD support groups may help educate patients on disease state and disease treatment knowledge. These support groups could be an ideal target for future education initiatives. Facebook enabled…
Facebook users who belong to a NASH support group seem to be more likely aware of what fatty liver disease is, and indicated that diet and exercise are helpful. Most have never spoken to a physician about fatty liver disease even though they are at high risk. Encouraging patients to join online NASH/NAFLD support groups may help educate patients on disease state and disease treatment knowledge. These support groups could be an ideal target for future education initiatives. Facebook enabled the rapid collection of a large number of responses in a short period of time.
Other authors -
-
Community Engagement and Cultural Competence Are Important for Positive Trans Donor Experiences
AABB Annual Meeting - Sunday, October 20, 2019 Conference Abstract and Poster
-
Who has the time? Nursing in a long-term care setting.
Senior Care Canada
A proof of concept study demonstrating the benefits of eMAR in long term care settings. Data from 18 nurses over a 2 week period showed a time savings of 1.1 hours per week per nurse. The study highlights the need for homes planning to implement eMAR to strategize and consider where to utilize and allocate the time saved.
Other authors -
-
Time and Motion Study. The Impact of eMAR.
OLTCA 2013 Conference Poster
A systematic comparison between homes using paper based medication records and homes using electronic medication administration records (eMAR). This Time and Motion study demonstrated a significant time savings in eMAR equipped homes.
Other authors -
-
Characterization of HBV Genotype Epidemiology and HBsAg Titres in Response to Anti-HBV Antiviral Therapy in Canadian Tertiary Referral Liver Centres
AASLD 2011 Poster
Other authors -
-
Epidemiology of HBV Genotypes in Two Large Canadian Tertiary Referral Centres.
Canadian Journal of Gatroenterology: Pulsus
Characteristics of the Calgary and Montreal patient population are listed below with comparisons made to previously published data from Toronto. Whereas 92% of Toronto patients had HBV genotypes B or C, these genotypes were identified in only 46% and 65% of Calgary and Montreal patients, respectively, although genotype C was still the most common. As most patients with genotypes B and C were Asian, Asian ethnicity was more common in patients from Toronto (90%) than in Calgary (63%) and Montreal…
Characteristics of the Calgary and Montreal patient population are listed below with comparisons made to previously published data from Toronto. Whereas 92% of Toronto patients had HBV genotypes B or C, these genotypes were identified in only 46% and 65% of Calgary and Montreal patients, respectively, although genotype C was still the most common. As most patients with genotypes B and C were Asian, Asian ethnicity was more common in patients from Toronto (90%) than in Calgary (63%) and Montreal (64%). Overall, 11% of Calgary patients were on anti-HBV treatment and 13% of the remainder qualified for therapy, with the majority being genotype C. In Montreal, 28% were on anti-HBV treatment and 18% of the untreated qualified for therapy.
Other authors -
Courses
-
4th NASH Summit
-
-
Breakthrough Communication Training: Horn Training and Consulting
-
-
Canadian Liver Meeting 2021 and 2022
-
-
Cantonese
-
-
Coaching Training: Horn Training and Consulting
-
-
Effective Listening: : LinkedIn Learning
-
-
Global Liver Institute A3 (Advanced Advocacy Academy)
-
-
IBT in Action, Zurich, Switzerland
-
-
INSEAD Marketing Champions Programme, Fountainbleu, France
-
-
Leading with Emotional Intelligence
Schulich
-
Professional Media Training: Mcnabmedia
-
Projects
-
NASHnet.ca
- Present
See projectDuring Covid-19 I launched this website to help NASH/NAFLD patients.
NASHnet provides current information about non-alcoholic fatty liver disease and NASH that patients and their families can trust by Physicians and Nurses who care about patients and their liver health.
Honors & Awards
-
CIHR Cafe Scientifique Grant
CIHR
For a community event in Westmount, Quebec, where we will have a fully interactive opportunity to engage with the community and offer free Fibroscan, Liver Health Assessments.
-
Canadian Liver Foundation 50th Anniversary Recognition Medal Winner
Canadian Liver Foundation
"Granting honours such as the 50th Anniversary Recognition Medal is a tangible and lasting way to pay tribute to those whose achievements or distinguished service to the Canadian Liver Foundation have benefited their fellow citizens, their community and their country."
-
National Sales Manager of the Year
Schering Canada Inc.
Received recognition as top National Sales Manager during 2000.
-
President's Club: Rep of the Year
Schering Canada Inc.
Received recognition as top sales performer in Ontario in the Hepatitis Division during 1994.
-
President's Club: Rep of the Year - Hospital Division
Schering Canada Inc.
Received recognition as top sales performer in the Hospital Division during 1991.
-
President's Club: Rep of the Year
Schering Canada Inc
Received recognition as top sales performer in Ontario in 1990.
-
President's Club: Rep of the Year
Schering Canada Inc.
Received recognition as top sales performer in Ontario during 1989.
Organizations
-
American Diabetes Association
Member
- PresentThere is a critical relationship between MASLD/MASH, Type-2 Diabetes and Obesity. FLA is very interested in sharing current insights from ADA with the liver community.
-
European Association for the Study of the Liver (EASL)
-
- PresentThe European Association for the Study of the Liver (EASL) is a European professional association for those researching liver disease.
-
Canadian Association for the Study of the Liver - CASL
Member
- PresentCASL is a multidisciplinary group of scientists and healthcare providers whose expertise focuses on the liver, and provides national leadership in all aspects of research, education and patient care as they pertain to the liver.
-
The International Network on Health and Hepatitis in Substance Users (INHSU)
Member
-The International Network on Health and Hepatitis in Substance Users (INHSU) is a global network dedicated to improving the health of people who use drugs, with a specific focus on hepatitis C, infectious diseases, and harms that can occur from drug use.
Recommendations received
16 people have recommended Michael
Join now to viewOther similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More